Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤REGAIN: 100% objective response rate, including five complete responses, among six evaluable patients
- ➤All eight REGAIN patients alive; median overall survival not reached at 6.9 months follow-up
- ➤FDA approved REGAIN expansion from 10 to up to 20 patients
- ➤IMPACT pancreatic cancer pilot completed enrollment with 48 patients across 10 clinical centers
- ➤Nine-month net loss widened to $98.9 million; cash and deposits totaled $99.8 million
Expert Statements
Uzi Sofer, CEO of Alpha Tau
“Alpha Tau has tremendous momentum right now, and the new fantastic interim data from our REGAIN trial in recurrent glioblastoma showcase the true power of Alpha DaRT,”
Uzi Sofer, CEO of Alpha Tau
“While the trial started with a focus on feasibility and safety, we initially begin to see responses to the treatment, and are now seeing this translate into patient survival. We will continue to follow these patients closely as their scans mature, but we believe they speak to what a potent, highly localized alpha-emitting therapy may be able to do in even the hardest-to-treat tumors. With the FDA having approved the expansion of REGAIN to up to 20 patients, which we believe may support market submission requirements for Alpha DaRT, we are pressing ahead with enrollment, while preparing for mass production and commercialization if and when we are able to secure such an authorization.”
Uzi Sofer, CEO of Alpha Tau
“The glioblastoma data reflect only one part of Alpha Tau’s much broader opportunity to meaningfully change how cancer is treated,”
Uzi Sofer, CEO of Alpha Tau
“In recent months we completed enrollment of 48 patients in our multicenter IMPACT pancreatic cancer pilot study, after three expansions driven by strong demand, and treated the first immunocompromised patient in our ADMIRE study. We now expect meaningful additional data from multiple trials in the coming months, including top-line data from our pivotal ReSTART trial in recurrent cSCC, initial data from IMPACT, and additional interim data from REGAIN.”
Uzi Sofer, CEO of Alpha Tau
“To be ready for the demand that we believe these data can generate, we continue to scale up our manufacturing capabilities. A central piece of that effort is bringing the first stage of our Hudson, New Hampshire plant online, which we are targeting to be ready for clinical trial supply by the end of 2026.”
Uzi Sofer, CEO of Alpha Tau
“On the corporate front, we are very pleased to have come home to Israel with our dual listing on the Tel Aviv Stock Exchange, quickly followed by our inclusion in the flagship TA-90 and TA-125 indices. With a strong balance sheet of $99.8 million, a growing body of clinical evidence across multiple tumor types, and a dense calendar of data readouts ahead of us, we believe Alpha Tau has never been better positioned to translate this momentum into meaningful impact for patients.”
- New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 Annual Meeting: all eight treated patients alive, with median overall survival not reached, and a 100% objective response rate, including five complete responses, in the first six evaluable patients at 6.9 months median follow-up, with 100% feasibility and no unanticipated serious adverse events -
- FDA approval to expand the REGAIN trial from 10 to up to 20 patients, which the Company believes could generate data that may support market submission requirements for Alpha DaRT(®) in recurrent glioblastoma -
Get started
Create a free account to read the full story.
